Target intelligence / Profile preview

Integrin and collagen-binding receptor

Molecular classification
Receptor, Cell adhesion molecule, Integrin family, Receptor tyrosine kinase
01

Overview

Cell-surface integrins and collagen-adhesion receptors, including the alpha-v integrin subfamily and discoidin domain receptors (DDR1 and DDR2), are primary mediators of fibroblast interaction with the extracellular matrix (ECM) (Humphries et al., 2019). These receptors are essential for sensing mechanical cues and regulating cell adhesion, migration, and the differentiation of fibroblasts into myofibroblasts during tissue repair (Leask, 2013). In pathological states, their persistent activation drives excessive ECM deposition, leading to organ fibrosis and contributing to the supportive stroma in various cancers (Valiathan et al., 2012). Therapeutic targeting of these receptors aims to interrupt pro-fibrotic signaling, such as the integrin-mediated activation of latent TGF-beta, which is a master regulator of fibrosis (Henderson et al., 2013). While these targets offer significant potential for treating fibroproliferative diseases, their involvement in normal physiological wound healing and tissue maintenance presents a challenge for achieving a favorable therapeutic index (Koivisto et al., 2014).

Other names
Collagen receptorsFibroblast adhesion receptorsCell-matrix adhesion moleculesIntegrin familyDiscoidin domain receptorsCollagen-binding integrins
02

Mechanism of action

Inhibition of ligand binding to cell-surface receptors to prevent downstream signaling, reduction of TGF-beta activation, and disruption of fibroblast-to-myofibroblast transition (Henderson et al., 2013; Borradori & Sonnenberg, 1999).

03

Biological functions

Cell adhesionSignal transductionExtracellular matrix remodelingCell migrationWound healingMyofibroblast differentiation
04

Disease associations

FibrosisCancerInflammationSclerodermaHypertrophic scarring
05

Safety considerations

Impaired wound healingPotential for systemic toxicity due to widespread expressionBleeding risksInterference with normal tissue homeostasis (Koivisto et al., 2014)
06

Interacting drugs

Abituzumab

5 more in the full profile.

07

Biomarkers

PRO-C3 (N-terminal propeptide of type III collagen)Integrin alpha-v beta-6 expressionDDR2 expression levels

Beyond the preview

Go deeper on Integrin and collagen-binding receptor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrin and collagen-binding receptor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call